Day One Biopharmaceuticals: Surging Momentum Raises Valuation Questions Amid High-Stakes Pipeline
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.